Biohaven’s ALS Drug Candidate Disappoints in Late-Stage Study

Verdiperstat, Biohaven’s investigational drug for amyotrophic lateral sclerosis (ALS), didn’t pass its phase 3 muster, failing to slow progression of the fatal muscle-wasting disease.
Source: Drug Industry Daily